Effect of the COVID-19 pandemic on asthma exacerbations in New Zealand: An interrupted time series analysis

BackgroundNew Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How this impacted asthma exacerbation rates in NZ is unknown. ObjectiveWe sou...

Full description

Saved in:
Bibliographic Details
Published inThe journal of allergy and clinical immunology. Global Vol. 2; no. 4; p. 100157
Main Authors Chan, Amy Hai Yan, Tomlin, Andrew, Chan, Eliza, Harrison, Jeff, Beyene, Kebede A.
Format Journal Article
LanguageEnglish
Published Elsevier 01.11.2023
Subjects
Asthma
COVID-19
exacerbations
hospitalizations
interrupted time series
public health
Online AccessGet full text

Cover

Abstract BackgroundNew Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How this impacted asthma exacerbation rates in NZ is unknown. ObjectiveWe sought to explore the effects of the COVID-19 restrictions on asthma exacerbations in NZ during 2020. MethodsWe used a population-based, interrupted time series to examine the impact of the first COVID-19 lockdown in NZ on asthma exacerbation rate. The primary outcome measure was change in the monthly exacerbation rate, defined as hospitalization and/or course of corticosteroids, before and after the first lockdown. In a secondary analysis, we quantified the number of patients with asthma, the actual asthma exacerbation rate from March to December 2019 versus March to December 2020, and the number of asthma hospitalizations. ResultsThere was a significant drop in the exacerbation rate immediately after lockdown (-3.02; P < .0001) followed by a significant and sustained increasing trend; the rate postlockdown increased relative to that prelockdown (0.27; P < .0001). Similar patterns were observed in all sociodemographic groups. In our secondary analysis, we identified 507,622 people with asthma; this reduced to 458,023 in 2020 postlockdown. The overall asthma exacerbation rate was 33.3% less in 2020 than in 2019 (reduction from 48.6/1000 patients to 32.4/1000 patients). The rate of asthma hospitalizations decreased from 9.5 per 1000 patients in 2019 to 6.2 per 1000 patients in 2020; this decrease was observed across all demographic groups. ConclusionsThe first COVID-19 lockdown in 2020 in NZ significantly reduced asthma exacerbation rates across all sociodemographic groups. Whether these reductions are sustained requires further investigation.
AbstractList Background: New Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How this impacted asthma exacerbation rates in NZ is unknown. Objective: We sought to explore the effects of the COVID-19 restrictions on asthma exacerbations in NZ during 2020. Methods: We used a population-based, interrupted time series to examine the impact of the first COVID-19 lockdown in NZ on asthma exacerbation rate. The primary outcome measure was change in the monthly exacerbation rate, defined as hospitalization and/or course of corticosteroids, before and after the first lockdown. In a secondary analysis, we quantified the number of patients with asthma, the actual asthma exacerbation rate from March to December 2019 versus March to December 2020, and the number of asthma hospitalizations. Results: There was a significant drop in the exacerbation rate immediately after lockdown (−3.02; P < .0001) followed by a significant and sustained increasing trend; the rate postlockdown increased relative to that prelockdown (0.27; P < .0001). Similar patterns were observed in all sociodemographic groups. In our secondary analysis, we identified 507,622 people with asthma; this reduced to 458,023 in 2020 postlockdown. The overall asthma exacerbation rate was 33.3% less in 2020 than in 2019 (reduction from 48.6/1000 patients to 32.4/1000 patients). The rate of asthma hospitalizations decreased from 9.5 per 1000 patients in 2019 to 6.2 per 1000 patients in 2020; this decrease was observed across all demographic groups. Conclusions: The first COVID-19 lockdown in 2020 in NZ significantly reduced asthma exacerbation rates across all sociodemographic groups. Whether these reductions are sustained requires further investigation.
BackgroundNew Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How this impacted asthma exacerbation rates in NZ is unknown. ObjectiveWe sought to explore the effects of the COVID-19 restrictions on asthma exacerbations in NZ during 2020. MethodsWe used a population-based, interrupted time series to examine the impact of the first COVID-19 lockdown in NZ on asthma exacerbation rate. The primary outcome measure was change in the monthly exacerbation rate, defined as hospitalization and/or course of corticosteroids, before and after the first lockdown. In a secondary analysis, we quantified the number of patients with asthma, the actual asthma exacerbation rate from March to December 2019 versus March to December 2020, and the number of asthma hospitalizations. ResultsThere was a significant drop in the exacerbation rate immediately after lockdown (-3.02; P < .0001) followed by a significant and sustained increasing trend; the rate postlockdown increased relative to that prelockdown (0.27; P < .0001). Similar patterns were observed in all sociodemographic groups. In our secondary analysis, we identified 507,622 people with asthma; this reduced to 458,023 in 2020 postlockdown. The overall asthma exacerbation rate was 33.3% less in 2020 than in 2019 (reduction from 48.6/1000 patients to 32.4/1000 patients). The rate of asthma hospitalizations decreased from 9.5 per 1000 patients in 2019 to 6.2 per 1000 patients in 2020; this decrease was observed across all demographic groups. ConclusionsThe first COVID-19 lockdown in 2020 in NZ significantly reduced asthma exacerbation rates across all sociodemographic groups. Whether these reductions are sustained requires further investigation.
ArticleNumber 100157
Author Harrison, Jeff
Beyene, Kebede A.
Chan, Amy Hai Yan
Tomlin, Andrew
Chan, Eliza
Author_xml – sequence: 1
  givenname: Amy Hai Yan
  orcidid: 0000-0002-1291-3902
  surname: Chan
  fullname: Chan, Amy Hai Yan
– sequence: 2
  givenname: Andrew
  surname: Tomlin
  fullname: Tomlin, Andrew
– sequence: 3
  givenname: Eliza
  surname: Chan
  fullname: Chan, Eliza
– sequence: 4
  givenname: Jeff
  surname: Harrison
  fullname: Harrison, Jeff
– sequence: 5
  givenname: Kebede A.
  surname: Beyene
  fullname: Beyene, Kebede A.
BookMark eNpNkU9v1DAQxS1UJErbT8DFRy5Z_Cd2Ym7VUmClil5KD71YY2fcOiTxYnsF_fakXYQ4zejp6Y3m_d6SkyUtSMg7zjaccf1h3Izg48NGMCFXhXHVvSKnoutE0wsjT_7b35CLUkbGmOg7YZg4JT-uQkBfaQq0PiLd3tztPjXc0D0sA87R07RQKPVxBoq_wWN2UGNaCo0L_Ya_6D3CtFo_0stllSrmfNhXHGiNM9KCOWKhsMD0VGI5J68DTAUv_s4z8v3z1e32a3N982W3vbxuvOSiazSYnruBS8cGYQRT6F3HW5CqbVUfXBtYUEF6ZZhG4ySANs5zANcxP2gtz8jumDskGO0-xxnyk00Q7YuQ8oOFXKOf0EqjPaJkDHpoUZje8QGVUhwDRzS4Zr0_Zu1z-nnAUu0ci8dpfRrTodi1SK6Vblm_WuXR6nMqJWP4d5oz-0zKjvaFlH0mZY-k5B9AhYlk
Cites_doi 10.1016/j.jaci.2020.09.017
10.1016/j.lanwpc.2020.100056
10.1016/S0140-6736(20)30922-3
10.1016/j.jaip.2021.01.003
10.1111/resp.14119
10.1136/thoraxjnl-2020-216380
10.1136/thoraxjnl-2021-216930
10.1016/j.jaip.2020.07.057
10.1002/ppul.25578
10.15585/mmwr.mm6915e3
10.1136/bmj.m3731
10.1016/S2468-2667(20)30225-5
10.1016/j.jaip.2020.04.053
10.1016/j.lanwpc.2021.100127
10.1136/thoraxjnl-2020-216512
10.1016/j.jaip.2020.09.060
10.1016/j.jaip.2021.04.038
10.1183/13993003.04493-2020
10.1136/bmjopen-2020-044726
10.1038/s41467-022-29402-5
ContentType Journal Article
DBID AAYXX
CITATION
7X8
DOA
DOI 10.1016/j.jacig.2023.100157
DatabaseName CrossRef
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 2772-8293
EndPage 100157
ExternalDocumentID oai_doaj_org_article_396cee300a8a4e298b1de5551ef1ee9e
10_1016_j_jacig_2023_100157
GroupedDBID .1-
.FO
0SF
53G
AALRI
AAXUO
AAYXX
ADVLN
AFJKZ
AFRHN
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
CITATION
EBS
FDB
GROUPED_DOAJ
M41
M~E
OK1
ROL
RPM
Z5R
7X8
ID FETCH-LOGICAL-c3127-6a981bd13b0d29205ecb714a354458fb4f0f5f3c5906e9b3aa69bc1aab70cd663
IEDL.DBID DOA
ISSN 2772-8293
IngestDate Fri Oct 04 13:02:44 EDT 2024
Wed Jul 24 17:51:24 EDT 2024
Thu Sep 26 18:44:19 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3127-6a981bd13b0d29205ecb714a354458fb4f0f5f3c5906e9b3aa69bc1aab70cd663
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-1291-3902
OpenAccessLink https://doaj.org/article/396cee300a8a4e298b1de5551ef1ee9e
PQID 2871656408
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_396cee300a8a4e298b1de5551ef1ee9e
proquest_miscellaneous_2871656408
crossref_primary_10_1016_j_jacig_2023_100157
PublicationCentury 2000
PublicationDate 2023-11-00
20231101
2023-11-01
PublicationDateYYYYMMDD 2023-11-01
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-00
PublicationDecade 2020
PublicationTitle The journal of allergy and clinical immunology. Global
PublicationYear 2023
Publisher Elsevier
Publisher_xml – name: Elsevier
References McClatchey (10.1016/j.jacig.2023.100157_bib5) 2021; 9
Skene (10.1016/j.jacig.2023.100157_bib26) 2021; 76
Gurney (10.1016/j.jacig.2023.100157_bib19) 2021; 10
Shah (10.1016/j.jacig.2023.100157_bib10) 2021; 76
Abe (10.1016/j.jacig.2023.100157_bib23) 2021; 9
Pareek (10.1016/j.jacig.2023.100157_bib30) 2020; 395
Dicker (10.1016/j.jacig.2023.100157_bib20) 2020; 10
Wee (10.1016/j.jacig.2023.100157_bib24) 2021; 57
Imlach (10.1016/j.jacig.2023.100157_bib25) 2022; 11
Jefferies (10.1016/j.jacig.2023.100157_bib12) 2020; 5
Philip (10.1016/j.jacig.2023.100157_bib27) 2022; 9
Chan (10.1016/j.jacig.2023.100157_bib1) 2020; 5
Clift (10.1016/j.jacig.2023.100157_bib2) 2020; 371
Skevaki (10.1016/j.jacig.2023.100157_bib11) 2020; 146
Fairweather (10.1016/j.jacig.2023.100157_bib21) 2021; 26
(10.1016/j.jacig.2023.100157_bib14) 2019
Hurst (10.1016/j.jacig.2023.100157_bib9) 2021; 56
Dhanasekaran (10.1016/j.jacig.2023.100157_bib29) 2022; 13
Kaye (10.1016/j.jacig.2023.100157_bib28) 2020; 8
De Boer (10.1016/j.jacig.2023.100157_bib7) 2021; 8
Taquechel (10.1016/j.jacig.2023.100157_bib6) 2020; 8
Garg (10.1016/j.jacig.2023.100157_bib3) 2020; 69
Davies (10.1016/j.jacig.2023.100157_bib22) 2021; 76
10.1016/j.jacig.2023.100157_bib13
10.1016/j.jacig.2023.100157_bib15
10.1016/j.jacig.2023.100157_bib17
10.1016/j.jacig.2023.100157_bib16
10.1016/j.jacig.2023.100157_bib18
Jackson (10.1016/j.jacig.2023.100157_bib4) 2021; 58
Salciccioli (10.1016/j.jacig.2023.100157_bib8) 2021; 9
References_xml – volume: 146
  start-page: 1295
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib11
  article-title: Asthma-associated risk for COVID-19 development
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2020.09.017
  contributor:
    fullname: Skevaki
– volume: 5
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib1
  article-title: The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55)
  publication-title: Lancet Regional Health-Western Pacific
  doi: 10.1016/j.lanwpc.2020.100056
  contributor:
    fullname: Chan
– volume: 395
  start-page: 1421
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib30
  article-title: Ethnicity and COVID-19: an urgent public health research priority
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30922-3
  contributor:
    fullname: Pareek
– volume: 9
  year: 2022
  ident: 10.1016/j.jacig.2023.100157_bib27
  article-title: Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey
  publication-title: BMJ Open Respir Res
  contributor:
    fullname: Philip
– ident: 10.1016/j.jacig.2023.100157_bib18
– ident: 10.1016/j.jacig.2023.100157_bib16
– volume: 11
  start-page: 1316
  year: 2022
  ident: 10.1016/j.jacig.2023.100157_bib25
  article-title: Seeking healthcare during lockdown: challenges, opportunities and lessons for the future
  publication-title: Int J Health Policy Manag
  contributor:
    fullname: Imlach
– volume: 9
  start-page: 2070
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib5
  article-title: COVID-19 information for people living with asthma: a rapid review of publicly available information
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2021.01.003
  contributor:
    fullname: McClatchey
– volume: 26
  start-page: 1041
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib21
  article-title: Impact of COVID-19 pandemic restrictions on the cardio-respiratory health of New Zealanders
  publication-title: Respirology
  doi: 10.1111/resp.14119
  contributor:
    fullname: Fairweather
– volume: 76
  start-page: 867
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib22
  article-title: Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2020-216380
  contributor:
    fullname: Davies
– year: 2019
  ident: 10.1016/j.jacig.2023.100157_bib14
– volume: 76
  start-page: 852
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib26
  article-title: Improved asthma control during the COVID-19 pandemic: are there lessons to be learnt?
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2021-216930
  contributor:
    fullname: Skene
– volume: 8
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib7
  article-title: Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort
  publication-title: BMJ Open Respir Res
  contributor:
    fullname: De Boer
– volume: 8
  start-page: 3378
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib6
  article-title: Pediatric asthma health care utilization, viral testing, and air pollution changes during the COVID-19 pandemic
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2020.07.057
  contributor:
    fullname: Taquechel
– ident: 10.1016/j.jacig.2023.100157_bib15
– volume: 58
  start-page: PA3563
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib4
  article-title: Exploring the psychological impact of the COVID-19 pandemic on adults with asthma: a qualitative study
  publication-title: Eur Respir J
  contributor:
    fullname: Jackson
– volume: 56
  start-page: 3166
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib9
  article-title: Reduced pediatric urgent asthma utilization and exacerbations during the COVID-19 pandemic
  publication-title: Pediatr Pulmonol
  doi: 10.1002/ppul.25578
  contributor:
    fullname: Hurst
– volume: 69
  start-page: 458
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib3
  article-title: Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020
  publication-title: Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6915e3
  contributor:
    fullname: Garg
– volume: 371
  start-page: m3731
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib2
  article-title: Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study
  publication-title: BMJ
  doi: 10.1136/bmj.m3731
  contributor:
    fullname: Clift
– volume: 5
  start-page: e612
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib12
  article-title: COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study
  publication-title: Lancet Public Health
  doi: 10.1016/S2468-2667(20)30225-5
  contributor:
    fullname: Jefferies
– ident: 10.1016/j.jacig.2023.100157_bib13
– volume: 8
  start-page: 2384
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib28
  article-title: Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2020.04.053
  contributor:
    fullname: Kaye
– ident: 10.1016/j.jacig.2023.100157_bib17
– volume: 10
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib19
  article-title: The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand–a country pursuing COVID-19 elimination
  publication-title: Lancet Regional Health Western Pacific
  doi: 10.1016/j.lanwpc.2021.100127
  contributor:
    fullname: Gurney
– volume: 76
  start-page: 860
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib10
  article-title: Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2020-216512
  contributor:
    fullname: Shah
– volume: 9
  start-page: 494
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib23
  article-title: Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2020.09.060
  contributor:
    fullname: Abe
– volume: 9
  start-page: 2896
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib8
  article-title: Effect of COVID-19 on asthma exacerbation
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2021.04.038
  contributor:
    fullname: Salciccioli
– volume: 57
  start-page: 2004493
  year: 2021
  ident: 10.1016/j.jacig.2023.100157_bib24
  article-title: Reduction in asthma admissions during the COVID-19 pandemic: consequence of public health measures in Singapore
  publication-title: Eur Respir J
  doi: 10.1183/13993003.04493-2020
  contributor:
    fullname: Wee
– volume: 10
  year: 2020
  ident: 10.1016/j.jacig.2023.100157_bib20
  article-title: Changes in demand for emergency ambulances during a nationwide lockdown that resulted in elimination of COVID-19: an observational study from New Zealand
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-044726
  contributor:
    fullname: Dicker
– volume: 13
  start-page: 1721
  year: 2022
  ident: 10.1016/j.jacig.2023.100157_bib29
  article-title: Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-29402-5
  contributor:
    fullname: Dhanasekaran
SSID ssj0002872902
Score 2.291269
Snippet BackgroundNew Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused...
Background: New Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused...
SourceID doaj
proquest
crossref
SourceType Open Website
Aggregation Database
StartPage 100157
SubjectTerms Asthma
COVID-19
exacerbations
hospitalizations
interrupted time series
public health
Title Effect of the COVID-19 pandemic on asthma exacerbations in New Zealand: An interrupted time series analysis
URI https://search.proquest.com/docview/2871656408
https://doaj.org/article/396cee300a8a4e298b1de5551ef1ee9e
Volume 2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fSxwxEA7Fh1IQaW3Fq_WYQh9dTW6T3Y1v1lauBetLFd_CJJuoJ-4d9wP653eS7NWDPvSlr0tgl5lk5psvs98w9omSDlLBpgrVSllIHQQdKckLp6XF0qmALvIdlz-q8bX8fqtuN0Z9xZ6wLA-cDXdS6orieMk5Nij9SDdWtF5RnvdBeK99ir5CbRRTk0QZEWiMrTsHzw1dE3QPd8dxXHgSHooJaSMVJcX-vwJyyjIXr9lODw_hLH_WG_bCd7vs5WV_Ab7LtjPNBvnvobfsMasPwzQAITk4v7r59qUQGmaRG36ihdMOcLG8f0Lwv9CRDTNDBw8dUHyDvrXxFM46iMoR8_lqRhgU4sh5iLvTLwB73ZJ37Pri68_zcdHPTyhcKUZ1UaEmUNqK0vI2DqVS3tlaSCyjAE8TrAw8qEAO0bzy2paIlbZOINqau5agyB7b6qad32fgW1s3NhAesLXUddBBWz8iF8jQtE3FB-xobUozyzIZZt0_NjHJ8iZa3mTLD9jnaO4_S6PGdXpAnje9582_PD9gH9fOMnQm4kUHdn66WphUBapK8ub9_3jRAXs1il1CiXj5wLaW85U_JCiytMO064aJI_oNQDHdqQ
link.rule.ids 315,786,790,870,2115,27957,27958
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+the+COVID-19+pandemic+on+asthma+exacerbations+in+New+Zealand%3A+An+interrupted+time+series+analysis&rft.jtitle=The+journal+of+allergy+and+clinical+immunology.+Global&rft.au=Amy+Hai+Yan+Chan%2C+PhD&rft.au=Andrew+Tomlin%2C+PGDipSci&rft.au=Eliza+Chan%2C+MSc&rft.au=Jeff+Harrison%2C+PhD&rft.date=2023-11-01&rft.pub=Elsevier&rft.eissn=2772-8293&rft.volume=2&rft.issue=4&rft.spage=100157&rft_id=info:doi/10.1016%2Fj.jacig.2023.100157&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_396cee300a8a4e298b1de5551ef1ee9e
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2772-8293&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2772-8293&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2772-8293&client=summon